Equine Internal Medicine

This 100% online CPD mini-module has been developed and aimed towards the more experienced veterinary surgeon. The module content has been developed by veterinary specialists at the forefront of current veterinary research.

The module will provide you with 25 hours of designation specific CPD. Over four weeks we will cover a different weekly topic in an area in which there may have been changes, advances or controversy in recent years.

The course is taught and tutored by Liverpool and other external veterinary specialists, following a similar format to the University of Liverpool’s CertAVP modules.  With online lectures, discussion boards and weekly MCQ tests designed to help support your learning this short Equine Internal Medicine mini-module will provide a fun and interactive way to ensure you keep up to date in your area of interest.

 

Course content:

 

Week 1: Equine myopathies

Speaker:

Prof Catherine McGowan BVSc MMACVSc DEIM DECEIM PhD FHEA MRCVS

Have we moved any further forward with myopathies in our equine patients? What do recent advances tell us about how we diagnose and treat clinical cases?  With a range of underlying aetiologies and predisposing causes equine myopathic disorders can be equally as frustrating for owners as for clinicians. This week’s comprehensive lectures include tips on diagnosis, nutritional management to minimise recurrence as well as an update on newer causes of myopathic disease such as myofibrillar myopathy.

 

Week 2: Antimicrobial use in equine patients - what do I need to know?

Speakers:

Cajsa Isgren BVetMed MSc CertAVP (ESO, ESST, ED) DipECVS MRCVS

Sarah Stoneham BVSc Cert ESM MRCVS

Dave Rendle BVSc MVM CertEM(IntMed) DipECEIM MRCVS

Why consider antimicrobials? Antimicrobials are one of the most commonly used drugs in equine practice and antimicrobial resistance is one of the largest threats to human and animal health. Antibiotic stewardship should be at the very heart of how we practice but as we spend time in practice we tend to become reliant on certain ingrained truths and develop protocols that we are comfortable with clinically and don’t question over time. This week we review rational use of antimicrobials in our equine patients: Do we over treat? How do we avoid selecting for multi drug resistant bacteria and what do we do with those cases? We also consider antimicrobial use in foals and neonates and why we should remember foals are not simply small horses. This week is far from a pharmacology refresher but a really crucial and thought provoking review of current understanding from some truly engaging speakers.

 

Week 3: Break week

 

Week 4: Cardiology: Perfecting your approach to equine cardiac disease

Speakers:

Harry Carslake MA VetMB DipACVIM MRCVS

Gayle Hallowell MA VetMB, PhD, Cert AVP (Veterinary Anaesthesia), DipACVECC, DipACVIM, PFHEA, FRCVS

Cardiology in equine practice can be challenging. This week focuses on the diagnosis, treatment and management of commonly encountered cardiac abnormalities including current recommendations for therapy where appropriate.

Starting right from the basics of how to get the most from your stethoscope, we will also consider further diagnostics such as “how to perform an exercising ECG” for those clinicians keen to go “beyond the stethoscope” including recognition of significant abnormalities, incidental findings and how these affect your clinical decision making. 

 

Week 5: Update on equine hepatic disease

Speaker:

Fernando Malalana DVM GPCert(EqP) DipECEIM MRCVS

Diagnosis, prognosis and determining the underlying aetiology in cases of equine hepatic disease is not always straightforward. In many cases liver disease may go unnoticed until it is too late to treat or in others we may detect liver damage on blood samples and need to advise the owner appropriately in the absence of clinical signs.

This week we will review the aetiology of equine liver disease including updates on the latest international work looking at the various causes of viral hepatitis and consider prognostic indicators. Finally we consider management of hepatic insufficiency and evidence for current therapies. 

 

 

Start date: 23 March 2020

Cost: £385